Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3277511A

Next Previous
Search
Drug Profile

GSK 3277511A

Alternative Names: GSK3277511; GSK3277511A; NTHi/Mcat-vaccine

Latest Information Update: 28 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • No development reported Respiratory tract disorders

Most Recent Events

  • 28 May 2022 No recent reports of development identified for phase-I development in Respiratory-tract-disorders(Prevention) in Belgium (IM, Injection)
  • 05 Sep 2021 Adverse events and immunogenicity data from a phase II trial in Chronic obstructive pulmonary disease was presented at the 31st Annual Congress of the European Respiratory Society
  • 13 Aug 2021 GlaxoSmithKline completes a phase II trial in Chronic obstructive pulmonary disease (Prevention, In adults, In the elderly) in Estonia, Finland, France, Italy and Spain (IM) (EudraCT2018-002977-24) (NCT03894969)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top